News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Antonio D’Alessio: Our work on neoadjuvant ICI in HCC has been chosen for the 2025 ASCO GI Merit Award
Antonio D'Alessio/X
Jan 19, 2025, 23:07

Antonio D’Alessio: Our work on neoadjuvant ICI in HCC has been chosen for the 2025 ASCO GI Merit Award

Antonio D’Alessio, Medical Oncologist and PhD student at Imperial College London, shared a post on X:

“Wonderful news – Conquer Cancer, the ASCO Foundation has chosen our work on neoadjuvant ICI in HCC for the 2025 ASCO GI Merit Award. Pathological or radiological response as best RFS predictor?

See you at my poster next Friday in San Francisco!”

Antonio D'Alessio: Our work on neoadjuvant ICI in HCC has been chosen for the 2025 ASCO GI Merit Award

Read further.

More posts featuring Antonio D’Alessio.

Antonio D'Alessio ASCO GI Merit Award cancer Conquer Cancer the ASCO Foundation HCC OncoDaily Oncology
Special Coverage
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Blog
Jan 19, 2025, 23:07
Antonio D'Alessio: Our work on neoadjuvant ICI in HCC has been chosen for the 2025 ASCO GI Merit Award
Science
Jan 19, 2025, 22:56
Bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab in pleural mesothelioma
Insight
Jan 19, 2025, 22:04
Chiaojung Jillian Tsai: TACE combined with Lenvatinib and Pembrolizumab vs Placebo for HCC
Science
Jan 19, 2025, 21:01
The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT)
Science
Jan 19, 2025, 20:59
Psychosocial impact associated with a multicancer early detection test (PATHFINDER)
Blog
Jan 19, 2025, 15:36
Paolo Tarantino: How do you plan to use Datopotamab Deruxtecan for HR+/HER2- MBC?
Science
Jan 19, 2025, 15:26
Andrea Necchi: Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with mCRPC
Insight
Jan 19, 2025, 15:23
Aleix Prat: Excited to share the results of the SOLTI-ELIPSE trial